menu
    • menu
    [{"orgOrder":0,"company":"Evexta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Rupitasertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Evexta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evexta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evexta Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Rupitasertib

    Menu

    Rupitasertib

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evexta Bio

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Evexta Bio

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rupitasertib,Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evexta Bio Reports Progress On Rupitasertib for Advanced Breast Cancer

                            Details : Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2024

                            Lead Product(s) : Rupitasertib,Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth